SAN FRANCISCO--(BUSINESS WIRE)--Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class disease-modifying therapies for chronic age-related diseases, presented to key opinion leaders in vivo efficacy data for its small molecule therapy targeting senescent cells that drive cellular aging to treat dermatological diseases. The data was presented during the 2023 American Academy of Dermatology (AAD) conference week, a gathering of the largest, most influential, and representative dermatology group, with a membership of more than 20,500 physicians worldwide. The focus of the annual conference is to help dermatological professionals learn about the latest industry updates and research.
Histopathological assessment showed that Rubedo’s lead compound significantly reduced senescence signatures associated with skin senescent cells, and significantly improved skin pathophysiological manifestations, such as chronic desquamation in preclinical animal models of chemotherapy-induced skin fibrosis and dermatitis.
“We’re excited to present for the first time, efficacy data of our lead compound that compares favorably to standard of care and supports further development,” said Ofir Moreno, Ph.D., Senior Vice President, Drug Discovery at Rubedo, who presented the data at the Oncodermatology Society conference. “By targeting the pathologic cells that drive aging, our approach has demonstrated a robust response targeting a fundamental mechanism which leads to inflammatory dermatological diseases such as chronic atopic dermatitis, plaque psoriasis, and chemotherapy-induced skin fibrosis and alopecia which are common side-effects of cancer treatment, and drivers of an accelerated biological aging process.”
The Oncodermatology Society conference held on March 17 in New Orleans, was chaired by Dr. Mario Lacouture, Professor and the Director of the Oncodermatology Program in the Dermatology Service, Department of Medicine, at Memorial Sloan Kettering Cancer Center in New York, and a Scientific Advisory Board member at Rubedo Life Sciences.
“We’re thrilled to present this data to key opinion leaders in the longevity field, ahead of our nomination of a clinical candidate for our dermatology program targeting skin senescent cell types that drive chronic degenerative dermatological conditions associated with biological aging processes,” said Marco Quarta, Ph.D., CEO & Founder, Rubedo Life Sciences.
Rubedo is planning first-in-human studies in multiple skin indications driven by chronic inflammation and degenerative fibrosis. Leveraging its proprietary single-cell multiomics platform ALEMBIC™, Rubedo identifies pathologic cells with senescence features characteristic of multiple dermatological chronic skin conditions, and is developing potent and selective compounds targeting those cells using its selective senolytic platform SenTech™.
About Rubedo Life Sciences
Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, technology, and life sciences, with expertise in drug development and commercialization from both large pharma and leading biotech companies. The company is based in Sunnyvale, CA. For additional information, visit www.rubedolife.com.
